Restarting production at the former Ben Venue facility in Ohio will be a “significant task” says Xellia Pharmaceuticals which plans to invest after buying the site from Hikma.
Manipulated employee records and English-only training materials were among violations cited by the US FDA at two Indian plants, but Sandoz is confident these will be resolved.
Thermofisher Scientific has stopped selling two agars used in pharmaceutical industry control labs, citing a worldwide shortage of the seaweed used to make them.
Eisai will sell its clinical diagnostics business – EIDIA Co. Ltd - to Sekisui Chemical for JPY 22.4bn ($183m).
Tweaks to EU orphan drug rules (OD) may be needed to accommodate Ebola treatment development and block industry attempts to delay generic entry says the European Commission.
AstraZeneca says it had no worries about giving rival Sanofi a potential blockbuster drug when the two exchanged compound library molecules this month.